Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
Kazia Therapeutics (NASDAQ: KZIA) has secured a Type C meeting with the FDA in December 2024 to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma multiforme (GBM). The meeting follows promising Phase II/III GBM-AGILE trial results announced in July 2024, where paxalisib showed meaningful improvement in overall survival for newly diagnosed unmethylated GBM patients. The drug has previously received both orphan drug and fast track designations from FDA. The company has updated its corporate presentation with preliminary GBM AGILE trial data and announced participation in upcoming medical conferences, including the Society for Neuro-Oncology Annual Meeting and San Antonio Breast Cancer Symposium.
Kazia Therapeutics (NASDAQ: KZIA) ha ottenuto un incontro di Tipo C con la FDA previsto per dicembre 2024 per discutere i potenziali percorsi di registrazione per paxalisib nel trattamento del glioblastoma multiforme (GBM) recentemente diagnosticato. L'incontro segue i risultati promettenti dello studio clinico di fase II/III GBM-AGILE annunciati a luglio 2024, nei quali paxalisib ha mostrato un significativo miglioramento della sopravvivenza globale per i pazienti con GBM non metilato appena diagnosticato. Il farmaco ha già ricevuto le designazioni di farmaco orfano e fast track dalla FDA. L'azienda ha aggiornato la sua presentazione aziendale con dati preliminari dello studio GBM AGILE e ha annunciato la sua partecipazione a prossimi congressi medici, inclusi l'Annual Meeting della Society for Neuro-Oncology e il San Antonio Breast Cancer Symposium.
Kazia Therapeutics (NASDAQ: KZIA) ha conseguido una reunión de tipo C con la FDA en diciembre de 2024 para discutir posibles vías de registro para paxalisib en glioblastoma multiforme (GBM) recién diagnosticado. La reunión sigue a los prometedores resultados de los ensayos de fase II/III de GBM-AGILE anunciados en julio de 2024, donde paxalisib mostró una mejora significativa en la supervivencia general para pacientes con GBM no metilados recién diagnosticados. El fármaco ya había recibido las designaciones de medicamento huérfano y vía rápida por parte de la FDA. La empresa ha actualizado su presentación corporativa con datos preliminares del ensayo GBM AGILE y ha anunciado su participación en próximas conferencias médicas, incluyendo la Reunión Anual de la Society for Neuro-Oncology y el Simposio sobre Cáncer de Mama de San Antonio.
Kazia Therapeutics (NASDAQ: KZIA)는 2024년 12월 FDA와의 C형 회의를 확보하여 paxalisib의 새롭게 진단된 다형성 교모세포종(GBM) 등록 경로에 대해 논의할 예정입니다. 이 회의는 2024년 7월 발표된 GBM-AGILE 2/3상 시험의 유망한 결과를 기반으로 하며, paxalisib은 새롭게 진단된 비 메틸화 GBM 환자에서 전체 생존율의 의미 있는 개선을 보여주었습니다. 이 약물은 이전에 FDA로부터 고아약 및 신속 심사 지정도 받았습니다. 회사는 GBM AGILE 시험의 초기 데이터를 포함한 기업 발표를 업데이트하고, Neuro-Oncology 연례 회의와 San Antonio Breast Cancer Symposium을 포함한 향후 의료 회의에 참가할 것이라고 발표했습니다.
Kazia Therapeutics (NASDAQ: KZIA) a obtenu une réunion de type C avec la FDA prévue en décembre 2024 pour discuter des voies potentielles d'enregistrement pour paxalisib dans le glioblastome multiforme (GBM) récemment diagnostiqué. Cette réunion fait suite à des résultats prometteurs de l'essai de phase II/III GBM-AGILE annoncés en juillet 2024, où paxalisib a montré une amélioration significative de la survie globale chez les patients nouvellement diagnostiqués avec un GBM non méthylé. Le médicament a déjà reçu les désignations de médicament orphelin et de voie rapide de la part de la FDA. L'entreprise a mis à jour sa présentation d'entreprise avec des données préliminaires de l'essai GBM AGILE et a annoncé sa participation à des conférences médicales à venir, y compris la réunion annuelle de la Society for Neuro-Oncology et le Symposium sur le cancer du sein de San Antonio.
Kazia Therapeutics (NASDAQ: KZIA) hat ein Typ-C-Meeting mit der FDA für Dezember 2024 gesichert, um mögliche Zulassungswege für paxalisib bei neu diagnostiziertem Glioblastom multiforme (GBM) zu erörtern. Das Meeting folgt auf vielversprechende Ergebnisse der Phase-II/III-Studie GBM-AGILE, die im Juli 2024 bekannt gegeben wurden, bei der paxalisib eine signifikante Verbesserung des Gesamtüberlebens bei neu diagnostizierten nicht methylierten GBM-Patienten zeigte. Das Medikament erhielt zuvor sowohl die Orphan-Drug- als auch die Fast-Track-Beantragung von der FDA. Das Unternehmen hat seine Unternehmenspräsentation mit vorläufigen Daten der GBM AGILE-Studie aktualisiert und die Teilnahme an bevorstehenden medizinischen Konferenzen, einschließlich des Kongresses der Society for Neuro-Oncology und des San Antonio Breast Cancer Symposium, angekündigt.
- FDA granted Type C meeting to discuss registration pathway for paxalisib
- Positive Phase II/III trial results showing meaningful survival improvement
- Drug holds both orphan drug and fast track FDA designations for GBM
- None.
Insights
The FDA granting a Type C meeting to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma represents a important regulatory milestone. The meeting follows promising Phase II/III GBM-AGILE trial results showing meaningful survival improvements in unmethylated GBM patients. This is particularly significant given paxalisib's existing orphan drug and fast track designations.
The blood-brain barrier penetrant PI3K/mTOR inhibitor addresses a critical unmet need in GBM treatment, where current options are The December meeting could potentially accelerate paxalisib's path to market, especially if the full secondary endpoint data expected later this year continues to show strong efficacy signals.
For a small-cap company (
Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM)
Company updates to corporate presentation and participation in upcoming medical meetings
In July 2024, the Company announced results from the Phase II/III clinical trial, GBM-AGILE, in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed clinically meaningful improvement in a prespecified secondary analysis for overall survival. Full data including secondary endpoints from the paxalisib arm of the GBM-AGILE study is expected to be presented at a scientific meeting later this year.
Paxalisib has previously received orphan drug designation and fast track designation from the FDA for glioblastoma in unmethylated MGMT promoter status patients, following radiation plus temozolomide therapy.
Updated corporate presentation
Today, the Company also announced that it has updated its corporate presentation, which now incorporates preliminary data from the GBM AGILE Phase II/III clinical trial evaluating paxalisib versus the standard of care for the treatment of in patients with glioblastoma. The updated presentation can be found at https://www.kaziatherapeutics.com/site/pdf/ebcc5b2e-29a6-410c-ab9a-c3e722413615/Kazia-Corporate-Presentation-November-2024.pdf
Participation in Upcoming and Recent Medical and Investor Conferences
The company plans on attending the following medical conferences in the fourth quarter of 2024:
- Society for Neuro-Oncology 29th Annual Meeting and Education Day, November 21-24, 2024, in
Houston, TX - San Antonio Breast Cancer Symposium, December 10-13, 2024, in
San Antonio, TX
These events provide Kazia with the opportunity to engage with key stakeholders and share the Company's vision to make a difference in the lives of patients by developing innovative cancer treatments. Kazia looks forward to meeting with investors in person at these events and invites discussion regarding partnering and investment opportunities.
Over the last several months, the Company has also participated and presented at a number of medical and investor conferences, including:
- H C Wainwright 26th Annual Global Investment Conference from Sep. 9-11, 2024
- 15th Biennial AACR Ovarian Cancer Research Symposium, Sep. 20 – 21, 2024
- Oppenheimer Oncology Summit, in collaboration with MD Anderson Cancer Center, Sep. 26, 2024
- American Society for Radiation Oncology Annual Meeting, Sep. 29 – Oct. 1, 2024
- Deerfield CEO Conference, Oct. 8-9, 2024
- Maxim Group's 2024 Healthcare Virtual Summit, Fireside Chat, Oct. 15, 2024
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in
Forward-Looking Statements
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
This announcement was authorized for release by Dr John Friend, CEO.
SOURCE Kazia Therapeutics Limited
FAQ
What is the purpose of Kazia Therapeutics' (KZIA) FDA Type C meeting in December 2024?
What were the results of KZIA's Phase II/III GBM-AGILE trial announced in July 2024?